Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.Go to original source...Go to PubMed...
Wrenger E, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. Br Med J 2003; 327: 147-149.Go to original source...Go to PubMed...
Schepkens H, et al. Life-threatening hyperkalemia during combined therapy with antiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
Juurlink DN, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551.Go to original source...Go to PubMed...
Peng C, et al. Retrospective Drug Utilization Review: Incidence of Clinically Relevant Potential Drug-Drug interactions in a Large Ambulatory Population. J Managed Care Pharm 2003; 9(6): 513-522.Go to original source...Go to PubMed...
Madam, Sir, please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert). Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.
I declare:
that I have met the above instruction
I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited